Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2026 · 10-Q
Revenue$174.06M$174.06M+12.3% vs Q1 2025 Net Income-$71.14M-$71.14MN/M vs Q1 2025 EPS Diluted-$0.62-$0.62N/M vs Q1 2025 Gross Profit$135,126,000+16.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$13,517,000N/M Free Cash Flowderived-$18,669,000N/M Margins · derivedGross margin77.6%+2.5 pt vs Q1 2025
Operating margin-38.7%−14.3 pt vs Q1 2025
Net margin-40.9%−18.7 pt vs Q1 2025
ended Mar 31, 2026 · filed Apr 30, 2026 · 30 d after period end